The path to the clinic: a comprehensive review on direct KRAS(G12C) inhibitors

The RAS oncogene is both the most frequently mutated oncogene in human cancer and the first confirmed human oncogene to be discovered in 1982. After decades of research, in 2013, the Shokat lab achieved a seminal breakthrough by showing that the activated KRAS isozyme caused by the G12C mutation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwan, Albert K., Piazza, Gary A., Keeton, Adam B., Leite, Caio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767686/
https://www.ncbi.nlm.nih.gov/pubmed/35045886
http://dx.doi.org/10.1186/s13046-021-02225-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767686/
https://www.ncbi.nlm.nih.gov/pubmed/35045886
http://dx.doi.org/10.1186/s13046-021-02225-w

Ejemplares similares